Join 84,000+ Looksmaxxing Members!

Register a FREE account today to become a member. Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox.

  • DISCLAIMER: DO NOT ATTEMPT TREATMENT WITHOUT LICENCED MEDICAL CONSULTATION AND SUPERVISION

    This is a public discussion forum. The owners, staff, and users of this website ARE NOT engaged in rendering professional services to the individual reader. DO NOT use the content of this website as an alternative to personal examination and advice from licenced healthcare providers. DO NOT begin, delay, or discontinue treatments and/or exercises without licenced medical supervision. Learn more

Info Water erda + theory

Hypertrophy

T3 to feel warm
Requested Ban
Reputable ★★★
Established ★
Joined
Apr 5, 2026
Messages
2,962
Solutions
16
Reputation
19,219
Erdafitinib is a pan fgfr inhibitor that acts on fgfrs 1-4

Erda is potent with IC50 values coming in at

1.2 nM fgfr1

2.5 nM fgfr2

3.0nM fgfr3

5.7nM fgfr4

Now let's get into it, normally in the epiphyseal plate fgfr3 is heavily expressed in the proliferation zone and once they become hypertrophic chondrocytes they predominantly express fgfr1

Fgfr3 activation → FRS2 → GRB2 → SOS → ras → raf → MEK → ERK → Brake on hypertrophic chondrocytes

Fgfr3 activation → PP2a activation → dephosphorylation of p107 → Inhibition of proliferating chondrocytes

Fgfr3 activation → STAT1 → nuclear translocation and activates cell cycle Inhibitor, p21 → inhibition of proliferating chondrocytes

Snail1 is also upregulated in the chondrocyte when fgfr3 is bound and is essential for STAT1 and MAPK signalling

Fgfr1 in the hypertrophic zone also works via similar mechanisms to inhibit how much those cells expand

fgfr2 in the growth plate helps with ossification and is located in the secondary ossification zone and also the perichondrium. Fgfr2 -/- mice had impaired PTHrP and ihh expression. This tells us that abaloparatide should be used if we inhibit fgfr2 heavily

The main fgfs that work on growth plate senescence is fgf 9 and 18

Fgfr3 Inhibition caused the physis in a patients wrist to widen, obviously because of the wider proliferation and hypertrophic zones. It also made another patients bone age stay two years behind his chronological age even post erdafitinib

The effects of erdafitinib are sex steroid independent and even with little signalling if growth factors involved (Ex. Early tanner stages ~2-3) skeletal overgrowth still occured. Probably because the growth factors that did act on his chondrocytes restored the AKT pathway but not the MAPK pathway

Normally fgfr3 downregulated AKT via GRB2 → GAB1 → PI3K → AKT downregulation

Dosing for erdafitinib for height:

Now this had me a little stumped but I figured it out, you must take clearance values, average concentration, converting ng/ml to nM, free fraction, and then running it through hills equation

Reference for 2mg erdafitinib in a healthy human

Cancer dose = 8mg

Cavg cancer patient = 1220ng/ml

Clearance cancer = 0.29

Clearance healthy = 0.43

Free fraction healthy = 0.510%

Desired dose = 2mg

Erdafitinib molecular weight = 447 g/mol

Now let's do this

Cavg healthy = 1,220 • 0.29/0.43 ≈ 823ng/ml

823 • 2/8 ≈ 206ng/ml

206/447 • 1000 = 461nM

461 • 0.00510 ≈ 2.35nM

FGFR2 = 2.35/2.35+2.5 ≈ 48% Inhibition

FGFR3 = 2.35/2.35+3.0 ≈ 43% Inhibition

Now that that's wrapped up, let's get theoretical.

Theory

Fgfr work in osteoblasts and suture mesenchymes in the skull. Now normally fgfr1/2/3 differentiation osteoblasts super quickly and immaturely. This causes alkaline phosphate window to decrease thus impaired hydroxyapatite.

Also immature osteoblasts release their own hydroxyapatite inhibiting signals, which is why we see a lot of fgfr deletion or activation genotypes to have poor mineralization with varying effects on bone mass and BMD

The fgfrs also inhibit bone marrow stem cells thus leaving the progenitor pool exhausted and also having less progenitors while pushing them to differentiate fast is a lot of stress

Hence why deletion genotypes still have poor mineralization, the sheer amount of progenitors just overlaps with each other and causes the system of mineralization to become sloppy.

Now Inhibition of let's say 50% of fgfr2 may help this problem and allow us to make some theoretical craniofacial gains. Now because fgfr2 is expressed in the suture mesenchymes, and taking these mesenchymal cells and differentiating them into osteoblasts super quickly via PKC→ runX2 → osteolineage

This means your sutures will differentiate slower because we are inhibiting this process. Also the more progenitors means more periosteal out growth (the fgfr deletion genotype had higher bone mass despite poorer mineralization )

Now according to implant studies, sutures experience growth after puberty, probably from strong mechanical forces. You see when a suture is histologically fused that's not the same as an implant study. A suture isn't just going to fuse one day you hit this age, it's going to gradually grow tiny bone bridges and eventually fuse completely way later in life.

And when implant studies experience the growth outside of puberty it's those little bone bridges breaking due to mechanical force but the get ossified quickly again by fgfr2

So we are essentially keeping sutures undifferentiated for longer and applying mechanical force via maxillary expansion device and orthodontic head gear to move the maxilla forward

Mechanical forces break the tiny bone bridges, so you could theoretically bonesmash whilst on erdafitinib to allow for other theoretical growth in your zygos, mandible and gonions

Then once we are done with erdafitinib, we are going to wait for the drug to leave our system once we get our head gear and expansion device unscrewed from the roof of our mouth we can then use PTHrP analog to rapidly ossify the spongy material we've created in our skull into bone

@saccharinesaint

@russian grey @NotFun @percghøst* @xorsizm @copevictim @Luffy @Jack Frost
 
Last edited:
Erdafitinib is a pan fgfr inhibitor that acts on fgfrs 1-4

Erda is potent with IC50 values coming in at

1.2 nM fgfr1

2.5 nM fgfr2

3.0nm fgfr3

5.7nM fgfr4

Now let's get into it, normally in the epiphyseal plate fgfr3 is heavily expressed in the proliferation zone and once they become hypertrophic chondrocytes they predominantly express fgfr1

Fgfr3 activation → FRS2 → GRB2 → SOS → ras → raf → MEK → ERK → Brake on hypertrophic chondrocytes

Fgfr3 activation → PP2a activation → dephosphorylation of p107 → Inhibition of proliferating chondrocytes

Fgfr3 activation → STAT1 → nuclear translocation and activates cell cycle Inhibitor, p21 → inhibition of proliferating chondrocytes

Snail1 is also upregulated in the chondrocyte when fgfr3 is bound and is essential for STAT1 and MAPK signalling

Fgfr1 in the hypertrophic zone also works via similar mechanisms to inhibit how much those cells expand

fgfr2 in the growth plate helps with ossification and is located in the secondary ossification zone and also the perichondrium. Fgfr2 -/- mice had impaired PTHrP and ihh expression. This tells us that abaloparatide should be used if we inhibit fgfr2 heavily

The main fgfs that work on growth plate senescence is fgf 9 and 18

Fgfr3 Inhibition caused the physis in a patients wrist to widen, obviously because of the wider proliferation and hypertrophic zones. It also made another patients bone age stay two years behind his chronological age even post erdafitinib

The effects of erdafitinib are sex steroid independent and even with little signalling if growth factors involved (Ex. Early tanner stages ~2-3) skeletal overgrowth still occured. Probably because the growth factors that did act on his chondrocytes restored the AKT pathway but not the MAPK pathway

Normally fgfr3 downregulated AKT via GRB2 → GAB1 → PI3K → AKT downregulation

Dosing for erdafitinib for height:

Now this had me a little stumped but I figured it out, you must take clearance values, average concentration, converting ng/ml to nM, free fraction, and then running it through hills equation

Reference for 2mg erdafitinib in a healthy human

Cancer dose = 8mg

Cavg cancer patient = 1220ng/ml

Clearance cancer = 0.29

Clearance healthy = 0.43

Free fraction healthy = 0.510%

Desired dose = 2mg

Erdafitinib molecular weight = 447 g/mol

Now let's do this

Cavg healthy = 1,220 • 0.29/0.43 ≈ 823ng/ml

823 • 2/8 ≈ 206ng/ml

206/447 • 1000 = 461nM

461 • 0.00510 ≈ 2.35nM

FGFR2 = 2.35/2.35+2.5 ≈ 48% Inhibition

FGFR3 = 2.35/2.35+3.0 ≈ 43% Inhibition

Now that that's wrapped up, let's get theoretical.

Theory

Fgfr work in osteoblasts and suture mesenchymes in the skull. Now normally fgfr1/2/3 differentiation osteoblasts super quickly and immaturely. This causes alkaline phosphate window to decrease thus impaired hydroxyapatite.

Also immature osteoblasts release their own hydroxyapatite inhibiting signals, which is why we see a lot of fgfr deletion or activation genotypes to have poor mineralization with varying effects on bone mass and BMD

The fgfrs also inhibit bone marrow stem cells thus leaving the progenitor pool exhausted and also having less progenitors while pushing them to differentiate fast is a lot of stress

Hence why deletion genotypes still have poor mineralization, the sheer amount of progenitors just overlaps with each other and causes the system of mineralization to become sloppy.

Now Inhibition of let's say 50% of fgfr2 may help this problem and allow us to make some theoretical craniofacial gains. Now because fgfr2 is expressed in the suture mesenchymes, and taking these mesenchymal cells and differentiating them into osteoblasts super quickly via PKC→ runX2 → osteolineage

This means your sutures will differentiate slower because we are inhibiting this process. Also the more progenitors means more periosteal out growth (the fgfr deletion genotype had higher bone mass despite poorer mineralization )

Now according to implant studies, sutures experience growth after puberty, probably from strong mechanical forces. You see when a suture is histologically fused that's not the same as an implant study. A suture isn't just going to fuse one day you hit this age, it's going to gradually grow tiny bone bridges and eventually fuse completely way later in life.

And when implant studies experience the growth outside of puberty it's those little bone bridges breaking due to mechanical force but the get ossified quickly again by fgfr2

So we are essentially keeping sutures undifferentiated for longer and applying mechanical force via maxillary expansion device and orthodontic head gear to move the maxilla forward

Mechanical forces break the tiny bone bridges, so you could theoretically bonesmash whilst on erdafitinib to allow for other theoretical growth in your zygos, mandible and gonions

Then once we are done with erdafitinib, we are going to wait for the drug to leave our system once we get our head gear and expansion device unscrewed from the roof of our mouth we can then use PTHrP analog to rapidly ossify the spongy material we've created in our skull into bone

@saccharinesaint

@russian grey @NotFun @percghøst* @xorsizm @copevictim @Luffy @Jack Frost
Good theory, bonesmashing while on erda would probably fuck up your skin even more thougj
 
I wrote this from memory in 30 mins 😓

More actual high effort coming soon maybe I'll see how much I wanna spoonfeed
Honestly, your knowledge sometimes amazes me. It would take me at least an hour to understand the connection between all these different mechanisms
 
I don't think I'll need your help — I'm thinking of making the next thread about KY19382, and it doesn't seem to be anything complicated. But I'm glad you're so responsive
Yes it would be interesting

Be wary of piezo1 feedback loop that affects the periosteum I think?
 
Can you tell me more about this?
So mechanical loading right? If we are going to use it for periosteal apposition right?

Wnt should be agonized and lots of other factors, people like using ky19382 to agonize wnt

If you nuke cxxc5 then you wont be able to really control the wnt/piezo1 feedback loop (piezo1 is a calcium channel that detects mechanical load and makes them into cellular signals)

Thus it would be really assymetrical deposition of extra cellular matrix and would look bad

Instead you should just lower cxxc5 instead of nuke. Also acute injury lowers cxxc5 I'm pretty sure which makes mechanical load lower cxxc5 alongside with ky19382 thus making the wnt/piezo1 loop more plausible

I'm pretty sure this effects the periosteum. Im unsure about growth plates I might need to brush up on this topic
 
So mechanical loading right? If we are going to use it for periosteal apposition right?

Wnt should be agonized and lots of other factors, people like using ky19382 to agonize wnt

If you nuke cxxc5 then you wont be able to really control the wnt/piezo1 feedback loop (piezo1 is a calcium channel that detects mechanical load and makes them into cellular signals)

Thus it would be really assymetrical deposition of extra cellular matrix and would look bad

Instead you should just lower cxxc5 instead of nuke. Also acute injury lowers cxxc5 I'm pretty sure which makes mechanical load lower cxxc5 alongside with ky19382 thus making the wnt/piezo1 loop more plausible

I'm pretty sure this effects the periosteum. Im unsure about growth plates I might need to brush up on this topic
Got it, thanks for the answer
 

Users who are viewing this thread

Back
Top